Ernexa Therapeutics (ERNAW) Share-based Compensation (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Share-based Compensation data on file, last reported at $309000.0 in Q1 2026.

• Quarterly Share-based Compensation fell 38.45% year-over-year to $309000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$52000.0 (down 102.99% YoY) and the FY2025 annual result came in at $1.4 million, down 39.13% from the prior year.
• Share-based Compensation improved to $309000.0 in Q1 2026, from -$1.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $2.9 million in Q4 2022 to a low of -$1.0 million in Q4 2025.
• A 5-year average of $510588.2 and a median of $405000.0 in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation soared 148.48% — and 2025, when it sank 349.27%.
• Tracing ERNAW's Share-based Compensation over 5 years: stood at $2.9 million in 2022, then slumped by 94.37% to $165000.0 in 2023, then soared by 148.48% to $410000.0 in 2024, then tumbled by 349.27% to -$1.0 million in 2025, then jumped by 130.23% to $309000.0 in 2026.
• The last three Share-based Compensation figures came in at $309000.0 (Q1 2026), -$1.0 million (Q4 2025), and $293000.0 (Q3 2025), per Business Quant data.